Commercial-Scale Biologics / mAb CDMOs
Biologics / mAb manufacturers on CDMO Signal: 20 listed, 20 with a Signal Score. Together they have 49 FDA inspections on file (including 23 NAI, 26 VAI and 0 OAI) and 145 EMA/MHRA GMP certificates. Fewer than three are fully evidenced (all four score pillars and at least one ClinicalTrials.gov match), so this page does not name a top three. The score does not measure expression host, validated bioreactor scale, or whether fill-finish is on the same site. Signal Score is computed from FDA inspection records, EMA EudraGMDP and MHRA GMP certificates, and ClinicalTrials.gov. CDMOs cannot pay to change it. Updated 2026-11-20. Methodology. This page is the commercial-scale filter: a high Signal Score or a broad ClinicalTrials.gov footprint. It is not a list of approved commercial products.
Biologics CDMOs manufacture monoclonal antibodies, fusion proteins, and other large molecules in mammalian (typically CHO) cell culture. It is the largest and most mature segment of contract manufacturing, spanning early clinical supply through multi-thousand-litre commercial production.
Selecting a biologics CDMO turns on bioreactor scale and modality fit (mAb, bispecific, fusion protein), titer and cell-line strategy, fill-finish, and — above all — a clean regulatory record at commercial scale. The rankings below score each CDMO on FDA inspection history, EMA/MHRA GMP certification, clinical-program activity, and capacity.
FDA inspection outcomes across these CDMOs: 23 NAI (no action), 26 VAI (voluntary action), 0 OAI (official action). Leading inspection & GMP sites: United States (31), Denmark (29), UNITED KINGDOM (29), Germany (21), Italy (16).
Last updated 2026-11-20. Sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.
Ranked by Signal Score (0–100). Fully evidenced marks a CDMO scored on all four pillars with at least one confirmed clinical program. Partly scored and profile-only CDMOs follow the scored rows. How we score
Showing contract manufacturers only.
| # | CDMO | Signal Score | Quality | FDA · GMP | Last FDA inspection | Capacity | Programs |
|---|---|---|---|---|---|---|---|
| 1 |
PC
|
90.1 | 100.0 | 4 insp · 14 GMP | 2025-12-16 · NAI | — | 366 programs |
| 2 |
PR
Lexington, KY · Riverview, MI · Ahmedabad, IN
|
86.9 | 96.0 | 7 insp · 15 GMP | 2026-02-13 · VAI | — | — |
| 3 |
FD
Research Triangle, NC · Holly Springs, NC · Hillerod, DK
Hiring · 20 open roles
|
86.7 | 100.0 | 0 insp · 35 GMP | None on file | — | |
| 4 |
AJ
San Diego, CA · Osaka, JP
|
83.5 | 100.0 | 0 insp · 1 GMP | None on file | — | — |
| 5 |
CD
Plankstadt, DE · Caponago, IT · Boulder, CO
|
83.1 | 99.3 | 5 insp · 17 GMP | 2025-11-14 · NAI | — | — |
| 6 |
RB
Hamburg, Germany
|
82.9 | 100.0 | 0 insp · 9 GMP | None on file | — | — |
| 7 |
MK
Darmstadt, DE · St. Louis, MO
Hiring · 8 open roles
Fully evidenced
Also makes its own products
|
81.9 | 98.8 | 2 insp · 2 GMP | 2025-04-28 · VAI | — | 22 programs |
| 8 |
LB
|
81.6 | 100.0 | 2 insp · 0 GMP | 2026-09-18 · NAI | — | — |
| 9 |
EF
Planegg, DE · San Diego, CA
|
81.6 | 100.0 | 7 insp · 0 GMP | 2026-05-15 · NAI | — | — |
| 10 |
EK
Birmingham, AL · Vancouver, BC
|
81.5 | 99.8 | 2 insp · 2 GMP | 2025-09-11 · NAI | — | — |
| 11 |
NW
|
80.8 | 100.0 | 0 insp · 8 GMP | None on file | Available | — |
| 12 |
SG
|
80.3 | 100.0 | 3 insp · 0 GMP | 2025-02-20 · NAI | — | — |
| 13 |
BR
|
80.3 | 97.2 | 6 insp · 10 GMP | 2026-05-13 · VAI | — | — |
| 14 |
CRA
|
79.5 | 100.0 | 2 insp · 18 GMP | 2025-12-02 · NAI | — | — |
| 15 |
AV
|
78.9 | 100.0 | 1 insp · 0 GMP | 2025-05-29 · NAI | — | — |
| 16 |
Oklahoma City, OK
|
78.6 | 98.2 | 1 insp · 0 GMP | 2026-06-17 · VAI | Available | — |
| 17 |
PG
Berlin, DE
|
78.1 | 100.0 | 0 insp · 4 GMP | None on file | — | — |
| 18 |
BT
Charlottetown, PE, Canada
|
76.5 | 99.4 | 1 insp · 0 GMP | 2022-08-26 · VAI | — | — |
| 19 |
KD
Woodbury, MN
|
76.1 | 98.5 | 3 insp · 9 GMP | 2025-11-13 · VAI | — | — |
| 20 |
AF
|
75.2 | 96.5 | 3 insp · 1 GMP | 2024-05-08 · VAI | — | — |